

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III VISTA trial for patients with previously untreated MM reported an increase in median overall survival of _____ after a follow-up period of 5 years for patients who received VMP in comparison to MP therapy.
a. 13.3 months
b. 43.1 months
c. 60 months
2. In a Phase I/II trial, CRd as first-line therapy for patients with MM generated high-quality responses but was associated with which of the following side effects?
a. Hyperglycemia
b. Anorexia
c. Proteinuria
d. All of the above
3. In a Phase I/II trial by Berdeja and colleagues, the administration of MLN9708 in combination with lenalidomide and dexamethasone produced a response rate of 100% in evaluable patients.
a. True
b. False
4. The RESORT trial demonstrated that rituximab re-treatment upon disease progression was as effective as rituximab maintenance in terms of time to treatment failure for patients with previously untreated, low tumor burden FL.
a. True
b. False
5. In the Phase III FIT trial of consolidation therapy with yttrium-90 ibritumomab tiuxetan after first remission in patients with advanced FL, patients who received consolidation therapy experienced a median progression-free survival advantage of approximately _____ versus patients who received no additional therapy.
a. 10 months
b. 22 months
c. 35 months
6. The SAKK-35/98 clinical trial, which evaluated a short course (4 weekly doses) of rituximab versus prolonged rituximab for patients with newly diagnosed or relapsed FL, did not report a prolonged event-free survival rate for patients who received prolonged rituximab.
a. True
b. False
7. The GAUSS study is evaluating obinutuzumab (GA101) versus _____ for patients with relapsed CD20-positive indolent B-cell NHL.
a. Bortezomib
b. Brentuximab vedotin
c. Rituximab
8. The Phase III COMFORT-I and COMFORT-II trials of ruxolitinib versus placebo and ruxolitinib versus best available therapy for MF did not demonstrate statistically significant and sustained reduction in spleen size in patients on the ruxolitinib study arms.
a. True
b. False
9. Study data with brentuximab vedotin presented at ASH 2010 demonstrated an overall response rate of 75% or higher for patients with _____.
a. Hodgkin lymphoma
b. Systemic anaplastic large T-cell lymphoma
c. Both a and b
10. Which of the following is an approved treatment for CML?
a. Dasatinib
b. Imatinib
c. Nilotinib
d. All of the above